RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Last chance for young adults to get vaccinated against HPV for free Today sees the launch of the ‘Do not miss out’ campaign, which calls on young people to get the first dose of the vaccine against the human papillomavirus (HPV) as soon as possible.
RIVM describes building blocks of future-proof soil strategy Soil use is becoming increasingly intensive. From use for agriculture and housing construction to recreation and infrastructure. At the same time, we also depend on the soil-watersystem for a healthy living environment, restore biodiversity, countering climate change, energy transition, absorption of rainwater and keeping groundwater clean.
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
One Health European Joint Programme (EJP) Expert Meeting On the 4th and 5th of June 2018, an expert meeting was held at RIVM to redefine and prioritise the topics for One Health research and integrative activities in Europe.